Head-to-head · Cost-Efficiency Index
Invigor Medical vs eMI Aesthetics
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicaleMI Aesthetics
Shoppers wanting compounded sema or tirz in all 50 states with an ai progress simulator.
Visit eMI AestheticsThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 70. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. eMI Aesthetics still earns a C — Shoppers wanting compounded sema or tirz in all 50 states with an ai progress simulator.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | eMI Aesthetics |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 70/100 |
| Semaglutide / mo | $199/mo | $179/mo (all doses, compounded) |
| Tirzepatide / mo | $339/mo | Not disclosed |
| Semaglutide / yr (modeled) | $2,388 | $2,148 |
| Tirzepatide / yr (modeled) | $4,068 | — |
| Coverage | Not disclosed | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #8 | #97 |
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
eMI Aesthetics
70/100Where the value is
- Available to eligible patients in all 50 states
- Offers both semaglutide and tirzepatide, plus an oral semaglutide option
- Intake and provider visits run through OpenLoop Health, an established telehealth network
The tradeoffs
- Full per-drug pricing is not shown before intake; only an 'as low as 179/month' starting rate is published
- No fill pharmacy or named medical director is publicly listed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.